Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer

NCT02770014 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.

NCT NCT02770014
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02770014 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer
Lead sponsor
Dana-Farber Cancer Institute
Phase
Phase 2
Overall status
Terminated
Start date
June 30, 2016
Completion date
June 19, 2019
Enrollment
43 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

epidermal growth factor receptor, non-small cell lung cancer